1. Comparing Treatment Alternatives in Ankylosing Spondylitis

3. Introduction

4. Program Overview

5. ASAS20 Responses in Patients With AS Treated With TNF and IL-17 Inhibitors

6. ASAS Partial Remission Responses With Anti-TNF Therapy

7. ASDAS Inactive Disease Responses With Anti-TNF Therapy

8. ASAS Partial Remission and ASDAS Inactive Disease With SEC

9. Biosimilar CT-P13 vs Reference IFX for the Treatment of AS: PLANETAS Study

10. ASAS-EULAR Recommendations for the Treatment of AS With bDMARDs

11. ASAS-EULAR Recommendations for the Treatment of AS With bDMARDs (cont)

12. AS: Outcome Measurements

13. ACR-SAA-SPARTAN 2015 Recommendations for the Treatment of AS and nr-axSpA

14. ACR-SAA-SPARTAN 2015 Recommendations for the Treatment of AS and nr-axSpA (cont)

15. ASAS-EULAR Recommendations for the Treatment of AS: Patients With IBD

16. Predictors of Clinical Response With Anti-TNF Treatment

17. Combination TNF Inhibitor Plus csDMARD Results in Improved Drug Retention in Patients With AS

18. ASAS-EULAR Recommendations Regarding Nonresponse to TNF Inhibitor

19. Loss of Response to TNF Inhibitor Therapy: Primary or Secondary Nonresponse?

20. Switching TNF Inhibitors in the Treatment of axSpA

21. Switching TNF Inhibitors in the Treatment of axSpA (cont)

22. General Contraindications to TNF Inhibitor Therapy

23. Inhibition of Radiographic Progression: TNF Inhibitors

24. Inhibition of Radiographic Progression: IL-17 Inhibitor

25. Comparative Efficacy Techniques

26. Comparative Efficacy Techniques (cont)

27. Comparative Efficacy Techniques (cont)

28. Comparative Efficacy and Safety of SEC and ADA in Patients With Active AS: A Bayesian Network Meta-Analysis of RCTs

29. Matching-Adjusted Indirect Comparison: ATLAS and MEASURE 2

30. Patient Baseline Characteristics in ATLAS and MEASURE 2 Before and After Matching

31. Comparative Effectiveness of SEC and ADA in AS: Matching-Adjusted Indirect Comparison Using All Phase 3 Pivotal Data

32. Comparative Effectiveness of SEC and GOL in AS: Matching-Adjusted Indirect Comparison Using All Phase 3 Pivotal Data

33. Clinical Insights Based on the Totality of Evidence

34. Clinical Insights Based on the Totality of Evidence (cont)

35. New Treatment Options and Emerging Drugs for AS

36. Head-To-Head RCTs in Patients With AS

37. Abbreviations

38. Abbreviations (cont)

39. Abbreviations (cont)

40. Abbreviations (cont)